Published in J Clin Oncol on March 23, 2009
Uncertainty in the translation of preclinical experiments to clinical trials. Why do most phase III clinical trials fail? Curr Gene Ther (2009) 1.33
Multiple treatment comparison meta-analyses: a step forward into complexity. Clin Epidemiol (2011) 1.16
Adjuvant chemotherapy for resected non-small-cell lung cancer: future perspectives for clinical research. J Exp Clin Cancer Res (2011) 1.00
Bayesian cohort and cross-sectional analyses of the PINCER trial: a pharmacist-led intervention to reduce medication errors in primary care. PLoS One (2012) 0.86
How close are we to customizing chemotherapy in early non-small cell lung cancer? Ther Adv Med Oncol (2011) 0.77
The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA (2001) 19.20
Equipoise and the ethics of clinical research. N Engl J Med (1987) 17.24
Use of the CONSORT statement and quality of reports of randomized trials: a comparative before-and-after evaluation. JAMA (2001) 13.36
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med (2004) 12.73
Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med (2002) 12.65
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med (2005) 10.58
MRI evaluation of the contralateral breast in women with recently diagnosed breast cancer. N Engl J Med (2007) 10.28
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Toward evidence-based medical statistics. 1: The P value fallacy. Ann Intern Med (1999) 6.50
Toward evidence-based medical statistics. 2: The Bayes factor. Ann Intern Med (1999) 5.78
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes. JAMA (1995) 3.73
Can meta-analyses be trusted? Lancet (1991) 3.43
Discussion sections in reports of controlled trials published in general medical journals: islands in search of continents? JAMA (1998) 3.34
Adaptive signature design: an adaptive clinical trial design for generating and prospectively testing a gene expression signature for sensitive patients. Clin Cancer Res (2005) 3.02
Bayesian methods in meta-analysis and evidence synthesis. Stat Methods Med Res (2001) 2.96
Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. J Natl Cancer Inst (2003) 2.95
A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. J Natl Cancer Inst (2000) 2.95
Bayes offers a 'new' way to make sense of numbers. Science (1999) 2.84
Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst (1997) 2.80
Methods for combining randomized clinical trials: strengths and limitations. Stat Med (1987) 2.49
A regulatory view on adaptive/flexible clinical trial design. Biom J (2006) 2.28
Chemotherapy for patients with non-small cell lung cancer: the surgical setting of the Big Lung Trial. Eur J Cardiothorac Surg (2004) 2.14
The CHART trials: Bayesian design and monitoring in practice. CHART Steering Committee. Stat Med (1994) 1.90
Modeling the impact of treatment and screening on U.S. breast cancer mortality: a Bayesian approach. J Natl Cancer Inst Monogr (2006) 1.73
Are all significant P values created equal? The analogy between diagnostic tests and clinical research. JAMA (1987) 1.64
A case for Bayesianism in clinical trials. Stat Med (1993) 1.59
Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol (2006) 1.51
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? For the proposal. Lancet Oncol (2006) 1.47
Application of an adaptive design to a randomized phase II selection trial in gastric cancer: a report of the study design. Pharm Stat (2006) 1.44
Are Bayes' days upon us? Statistical methods could change the conduct of clinical trials. J Natl Cancer Inst (2006) 1.42
Application of Bayesian statistics to decision making during a clinical trial. Stat Med (1992) 1.35
A score for Bayesian genome screening. Genet Epidemiol (2003) 1.33
On some applications of Bayesian methods in cancer clinical trials. Stat Med (1992) 1.28
Predicting time to prostate cancer recurrence based on joint models for non-linear longitudinal biomarkers and event time outcomes. Stat Med (2002) 1.26
Tutorial in biostatistics Bayesian data monitoring in clinical trials. Stat Med (1997) 1.21
Bayesian subset analysis in a colorectal cancer clinical trial. Stat Med (1992) 1.19
The what, why and how of Bayesian clinical trials monitoring. Stat Med (1994) 1.16
Lack of benefit of maintenance paclitaxel in first-line chemotherapy in metastatic breast cancer. J Clin Oncol (2006) 1.14
Estimation of mortality rates for disease simulation models using Bayesian evidence synthesis. Med Decis Making (2006) 1.14
Domiciliary thrombolysis by general practitioners. BMJ (1992) 1.11
Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. Control Clin Trials (2003) 1.09
The evolving role of MRI in the detection and evaluation of breast cancer. N Engl J Med (2007) 1.03
A unified method for monitoring and analysing controlled trials. Stat Med (1994) 0.93
Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res (2006) 0.93
Effect of circulating blasts at time of complete remission on subsequent relapse-free survival time in newly diagnosed AML. Blood (2003) 0.92
A correlated frailty model with long-term survivors for estimating the heritability of breast cancer. Stat Med (2007) 0.91
Adjuvant chemotherapy for completely resected non-small cell lung cancer: a systematic review. Crit Rev Oncol Hematol (2006) 0.88
Adjuvant treatment of lung cancer: current status and potential applications of new regimens. Lung Cancer (2004) 0.87
Time trends of breast cancer mortality in Spain during the period 1977-2001 and Bayesian approach for projections during 2002-2016. Ann Oncol (2006) 0.86
Where's the utility in Bayesian data-monitoring of clinical trials? Clin Trials (2005) 0.85
Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res (2000) 0.85
Is Bayesian analysis ready for use in phase III randomized clinical trials? Beware the sound of the sirens. Stroke (2005) 0.84
Why Bayesian analysis hasn't caught on in healthcare decision making. Int J Technol Assess Health Care (2001) 0.84
Large sample Bayesian inference on the parameters of the proportional hazard models. Stat Med (1997) 0.83
Clinical trials: is the Bayesian approach ready for prime time? Yes! Stroke (2005) 0.83
Adjuvant chemotherapy in non-small cell lung cancer (NSCLC). Ann Oncol (2007) 0.79
Adjuvant chemotherapy for non-small cell lung cancer. J Thorac Oncol (2007) 0.78
The Bayesian principle: can we adapt? Stroke (2005) 0.77
Can Bayesian methods make data and analyses more relevant to decision makers? A perspective from Medicare. Int J Technol Assess Health Care (2001) 0.77
Introduction to Bayesian reasoning. Int J Technol Assess Health Care (2001) 0.76
Bayesian analysis and the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator in Occluded Arteries. JAMA (1995) 0.76
Should adjuvant chemotherapy become standard treatment for patients with stage II colon cancer? Against the proposal. Lancet Oncol (2006) 0.76
Adjuvant chemotherapy for non-small-cell lung cancer: the end of the beginning. J Natl Cancer Inst (2003) 0.76
Postoperative adjuvant therapy for non-small cell lung cancer: a consensus report. Lung Cancer (1994) 0.76
Bayesian estimation of false-negative rate in a clinical trial of sentinel node biopsy. Stat Med (2007) 0.76
A Bayesian approach to a patient with a residual mass after treatment for non-Hodgkin's lymphoma of the thyroid. J Clin Oncol (2005) 0.76
Consensus conference on medical treatment of non-small cell lung cancer: adjuvant treatment. Lung Cancer (2002) 0.76
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 36.78
Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med (2010) 29.06
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol (2009) 15.23
Detection of mutations in EGFR in circulating lung-cancer cells. N Engl J Med (2008) 13.54
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med (2012) 10.20
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol (2008) 9.43
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine. EMBO Mol Med (2010) 6.38
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol (2007) 5.55
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
Cellular and genetic diversity in the progression of in situ human breast carcinomas to an invasive phenotype. J Clin Invest (2010) 4.22
Timeline: Chemotherapy and the war on cancer. Nat Rev Cancer (2005) 4.16
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib. Clin Cancer Res (2006) 4.11
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol (2005) 4.04
Pasireotide for postoperative pancreatic fistula. N Engl J Med (2014) 3.84
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol (2005) 3.51
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol (2007) 3.50
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer. J Clin Oncol (2010) 3.40
Development and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysis. Lancet Oncol (2009) 3.26
Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res (2007) 3.24
Tumor mitotic rate, size, and location independently predict recurrence after resection of primary gastrointestinal stromal tumor (GIST). Cancer (2008) 3.10
Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care. J Clin Oncol (2011) 2.95
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol (2004) 2.93
Preoperative characterisation of clear-cell renal carcinoma using iodine-124-labelled antibody chimeric G250 (124I-cG250) and PET in patients with renal masses: a phase I trial. Lancet Oncol (2007) 2.83
Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer. J Clin Oncol (2010) 2.80
Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol (2010) 2.56
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol (2007) 2.52
Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors. Ann Thorac Surg (2008) 2.47
A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid (2008) 2.41
Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy. Nature (2012) 2.28
Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg (2009) 2.27
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
Evolutionary pathways in BRCA1-associated breast tumors. Cancer Discov (2012) 2.01
Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg (2010) 1.98
Genetic and phenotypic diversity in breast tumor metastases. Cancer Res (2014) 1.96
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer. J Clin Oncol (2008) 1.94
HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J Clin Invest (2010) 1.93
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res (2004) 1.91
The New American Joint Committee on Cancer/International Union Against Cancer staging system for adenocarcinoma of the stomach: increased complexity without clear improvement in predictive accuracy. Ann Surg Oncol (2012) 1.87
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J Clin Oncol (2006) 1.86
Prognostic significance of pathologic nodal status in patients with resected pancreatic cancer. J Gastrointest Surg (2007) 1.86
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin Cancer Res (2009) 1.79
A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann Surg (2008) 1.76
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist (2007) 1.75
Phase I trial of systemic oxaliplatin combination chemotherapy with hepatic arterial infusion in patients with unresectable liver metastases from colorectal cancer. J Clin Oncol (2005) 1.73
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol (2010) 1.73
Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer. J Thorac Oncol (2010) 1.71
Laparoscopic adrenalectomy for isolated adrenal metastasis. Ann Surg Oncol (2007) 1.71
Diagnostic accuracy of 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med (2007) 1.69
18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med (2010) 1.63
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision. J Clin Oncol (2003) 1.63
Treating primary liver cancer with hepatic arterial infusion of floxuridine and dexamethasone: does the addition of systemic bevacizumab improve results? Oncology (2011) 1.61
Comparison of adjuvant systemic chemotherapy with or without hepatic arterial infusional chemotherapy after hepatic resection for metastatic colorectal cancer. Ann Surg (2011) 1.57
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev (2002) 1.54
2-[18F]fluoro-2-deoxyglucose positron emission tomography for the detection of disease in patients with prostate-specific antigen relapse after radical prostatectomy. Clin Cancer Res (2005) 1.53
Simple measurement of intra-abdominal fat for abdominal surgery outcome prediction. Arch Surg (2010) 1.52
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med (2008) 1.46
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology. Lung Cancer (2002) 1.46
18F-FDG PET/CT for detecting nodal metastases in patients with oral cancer staged N0 by clinical examination and CT/MRI. J Nucl Med (2006) 1.46
Reliability of adverse symptom event reporting by clinicians. Qual Life Res (2011) 1.45
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res (2002) 1.45
Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients. J Clin Oncol (2007) 1.42
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study. Lung Cancer (2004) 1.42
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol (2008) 1.42
Characterization of T-cell lymphomas by FDG PET/CT. AJR Am J Roentgenol (2010) 1.40
Prognostic value of baseline [18F] fluorodeoxyglucose positron emission tomography and 99mTc-MDP bone scan in progressing metastatic prostate cancer. Clin Cancer Res (2010) 1.40
Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res (2006) 1.40
Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.38
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res (2005) 1.36
Aggressiveness of care in a prospective cohort of patients with advanced NSCLC. Cancer (2008) 1.33
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer. Carcinogenesis (2005) 1.33
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev (2003) 1.33
Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk. Cancer Res (2002) 1.33
The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients. J Thorac Oncol (2009) 1.33
Solid pseudopapillary tumors of the pancreas. Clinical features, surgical outcomes, and long-term survival in 45 consecutive patients from a single center. J Gastrointest Surg (2010) 1.33
Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev (2005) 1.33
Predicting survival after curative colectomy for cancer: individualizing colon cancer staging. J Clin Oncol (2011) 1.32
Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol (2008) 1.31
Gallbladder cancer: differences in presentation, surgical treatment, and survival in patients treated at centers in three countries. J Am Coll Surg (2010) 1.31
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk. Cancer Causes Control (2008) 1.25
XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk. Carcinogenesis (2007) 1.25
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer. Clin Cancer Res (2008) 1.24
A simulation study to evaluate the impact of the number of lesions measured on response assessment. Eur J Cancer (2008) 1.24
Outcome of metastatic GIST in the era before tyrosine kinase inhibitors. Ann Surg Oncol (2006) 1.23
Bayesian clinical trials: no more excuses. Clin Trials (2009) 1.23
Screening for cancer with PET and PET/CT: potential and limitations. J Nucl Med (2007) 1.22
Teams: communication in multidisciplinary care. Oncologist (2006) 1.22
Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol (2013) 1.21
Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma. Ann Surg Oncol (2008) 1.19
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial. J Clin Oncol (2005) 1.19
Second hand smoke, age of exposure and lung cancer risk. Lung Cancer (2008) 1.19
Practical approach for comparative analysis of multilesion molecular imaging using a semiautomated program for PET/CT. J Nucl Med (2011) 1.18
Laughter: the best medicine? Oncologist (2005) 1.15
Comparing ROC curves derived from regression models. Stat Med (2012) 1.15
Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer. Carcinogenesis (2008) 1.15
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. J Clin Oncol (2007) 1.12